CA2096196A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
CA2096196A1
CA2096196A1 CA002096196A CA2096196A CA2096196A1 CA 2096196 A1 CA2096196 A1 CA 2096196A1 CA 002096196 A CA002096196 A CA 002096196A CA 2096196 A CA2096196 A CA 2096196A CA 2096196 A1 CA2096196 A1 CA 2096196A1
Authority
CA
Canada
Prior art keywords
cis
vitamin
retinoic acid
treatment
cis retinoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002096196A
Other languages
English (en)
French (fr)
Inventor
Werner Bollag
Manfred Brockhaus
Willi Hunziker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2096196A1 publication Critical patent/CA2096196A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002096196A 1992-05-20 1993-05-13 Pharmaceutical compositions Abandoned CA2096196A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1619/92 1992-05-20
CH161992 1992-05-20
CH926/93 1993-03-26
CH92693 1993-03-26

Publications (1)

Publication Number Publication Date
CA2096196A1 true CA2096196A1 (en) 1993-11-21

Family

ID=25686129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096196A Abandoned CA2096196A1 (en) 1992-05-20 1993-05-13 Pharmaceutical compositions

Country Status (12)

Country Link
EP (1) EP0579915A1 (enrdf_load_html_response)
JP (1) JPH0632740A (enrdf_load_html_response)
KR (1) KR940005278A (enrdf_load_html_response)
CN (1) CN1080525A (enrdf_load_html_response)
AU (1) AU3716193A (enrdf_load_html_response)
CA (1) CA2096196A1 (enrdf_load_html_response)
CZ (1) CZ83293A3 (enrdf_load_html_response)
HU (1) HUT66864A (enrdf_load_html_response)
IL (1) IL105700A0 (enrdf_load_html_response)
NO (1) NO931831L (enrdf_load_html_response)
NZ (1) NZ247630A (enrdf_load_html_response)
TW (1) TW272187B (enrdf_load_html_response)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US6242435B1 (en) 1998-07-16 2001-06-05 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
AU739440B2 (en) * 1997-08-23 2001-10-11 Basilea Pharmaceutica Ag Treatment of cell-mediated immune diseases
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US8541469B2 (en) 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461622B2 (en) * 1994-09-07 2002-10-08 Johnson & Johnson Consumer Companies, Inc. Topical compositions
DK128494A (da) * 1994-11-08 1996-05-09 Edel K Seidenschnur Behandling af keratinøse og psoriatiske sygdomstilstande med neglelak indeholdende vitamin D metabolit, eller derivat, og/eller vitamin A derivat
WO1997011703A1 (fr) * 1995-09-28 1997-04-03 Teijin Limited Preventif ou remede contre l'hyperthyroidie
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5827878A (en) * 1996-07-01 1998-10-27 Nisshin Flour Milling Co., Ltd. Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-α-tocopherol ester
US5891865A (en) * 1996-10-04 1999-04-06 Wisconsin Alumni Research Foundation Treatment of arthritic disease induced by infectious agents
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6733779B2 (en) * 1999-08-26 2004-05-11 L. Dean Parks Method of treating benign prostatic hyperplasia and other benign prostate conditions
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
US6339107B1 (en) 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
RU2168996C1 (ru) * 2000-09-19 2001-06-20 Фармацевтическое научно-производственное предприятие "Ретиноиды" (акционерное общество закрытого типа) Стабильный раствор ретинола пальмитата и способ лечения заболеваний кожи
JP2002104995A (ja) * 2000-09-29 2002-04-10 Masahiko Hosaka テロメラーゼ活性抑制剤
JP4326159B2 (ja) 2001-02-09 2009-09-02 株式会社ジェイテクト 玉軸受
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
BRPI0410646A (pt) * 2003-05-20 2006-07-04 Ranbaxy Lab Ltd composições farmacêuticas de acitretina e processo para sua preparação
WO2005102296A2 (en) * 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
CN102727476B (zh) * 2012-06-14 2014-05-14 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治骨质疏松药物中的应用
JP2019014676A (ja) * 2017-07-06 2019-01-31 東海カプセル株式会社 カプセル剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360910A (ja) * 1986-09-01 1988-03-17 Shiseido Co Ltd 皮膚外用剤

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
AU739440B2 (en) * 1997-08-23 2001-10-11 Basilea Pharmaceutica Ag Treatment of cell-mediated immune diseases
US8541469B2 (en) 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US6242435B1 (en) 1998-07-16 2001-06-05 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6479474B2 (en) 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis

Also Published As

Publication number Publication date
IL105700A0 (en) 1993-09-22
KR940005278A (ko) 1994-03-21
CN1080525A (zh) 1994-01-12
AU3716193A (en) 1993-11-25
HUT66864A (en) 1995-01-30
TW272187B (enrdf_load_html_response) 1996-03-11
NZ247630A (en) 1995-12-21
JPH0632740A (ja) 1994-02-08
EP0579915A1 (de) 1994-01-26
NO931831L (no) 1993-11-22
CZ83293A3 (en) 1993-12-15
HU9301404D0 (en) 1993-09-28
NO931831D0 (no) 1993-05-19

Similar Documents

Publication Publication Date Title
CA2096196A1 (en) Pharmaceutical compositions
US5451574A (en) Vitamin D3 Flourinated Analogs
JP4511838B2 (ja) （２０Ｓ）−１α−ヒドロキシ−２α−メチル及び２β−メチル−１９−ノル−ビタミンＤ３及びそれらの使用
EP0771789B1 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
KR930011151B1 (ko) 세포 분화의 유발에 유효한 화합물
RU2136660C1 (ru) Аналоги витамина d, способы их получения и фармацевтическая композиция
JP2859247B2 (ja) ビタミンｄ３類似体
LV10428B (en) Novel vitamin d analogues
JP2670005B2 (ja) ビタミンｄ３フツ素化同族体
EP0322004B1 (en) Cyclic anti-inflammatory derivatives of di-tert-butylphenol compounds
US5750517A (en) Method of treating sebaceous gland diseases with vitamin D3 fluorinated analogs
RU2142803C1 (ru) Агент для лечения заболеваний сальной железы и фармацевтическая композиция на его основе
BG60530B2 (bg) Дехидрохолекалцифероли
PT808831E (pt) Analogos fluorados de vitamina d3
JPH0127044B2 (enrdf_load_html_response)
JP4763603B2 (ja) （２０Ｓ）−１α−ヒドロキシ−２−メチレン−１９−ノル−ビタミンＤ３及びその使用
JPH07508515A (ja) ビタミンｄ系列の２２−エン−２５−オキサ−誘導体，該化合物の製造法，該誘導体を含有する薬学的調剤ならびに薬剤としての該調剤の使用
JP2677520B2 (ja) ビタミンｄ３−類似体
PL176017B1 (pl) Nowe analogi witaminy D, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne.
EP0983221B1 (en) Cyclohexanediol derivatives
RU2175318C2 (ru) Производные витамина d3, способы его получения, фармацевтическая композиция
KR20010109357A (ko) 비타민 ｄ 동족체 및 이의 약제학적 용도
JP2005503434A (ja) ３−デスオキシ−ビタミンｄ３類似体
JPWO2003070716A1 (ja) ビタミンｄ３誘導体およびそれを用いる治療剤
CA2235584A1 (en) 24-homo-26,27-hexafluoro-cholecalciferols

Legal Events

Date Code Title Description
FZDE Discontinued